Trump Replaces Attorney General Amid Marijuana Rescheduling Push, Uncertainty Remains

The Trump administration has replaced Attorney General Pam Bondi, who was tasked with expediting the federal rescheduling of marijuana, with former personal lawyer Todd Blanche as acting attorney general. The shakeup comes just months after Trump signed a December 18 executive order instructing the attorney general to move cannabis to Schedule III "in the most expeditious manner possible." According to High Times, Bondi’s departure has raised questions about whether this leadership change will impact the timeline or outcome of marijuana rescheduling

Despite the abrupt change, industry sources and legal observers indicate that the process to reclassify marijuana is expected to continue without major disruption. "Trump has been clear in his directive," said Brian Vicente, who emphasized that the administration seems committed to ensuring the process is legally and procedurally sound. In addition, Jushi executive Trent Woloveck described Blanche as "a big net positive" who is already familiar with the issue and has participated in discussions on drafting the final rule

The ongoing debate within the cannabis community centers not only on the logistics of rescheduling but also on what Schedule III status would actually accomplish. As High Times notes, rescheduling cannabis does not equate to federal legalization, nor does it automatically enable interstate commerce, expungement of criminal records, or broad criminal justice reform. While some operators may benefit from changes to tax regulations, the move could also introduce greater federal oversight and exclude certain stakeholders from the new regulatory framework

Blanche's appointment brings a new dynamic to the process, as he is not a typical Department of Justice official but Trump's former personal attorney, now elevated to a key government position. This change may intensify the political complexities surrounding the issue, as the White House continues to frame cannabis reform in strictly medical terms rather than as a matter of broader legalization. Legal challenges are anticipated, with organizations like Smart Approaches to Marijuana (SAM) expected to contest any final rule, similar to their recent lawsuit against a federal hemp reimbursement pilot program

Even if the rescheduling process proceeds smoothly, experts caution that tangible benefits such as tax relief may not materialize quickly due to potential legal battles and procedural delays. High Times points out that, "the real-world benefits may not arrive quickly," and even tax advantages are not guaranteed to be as straightforward as some anticipate. The administration's recent policy moves, including the CMS hemp reimbursement pilot, signal continued interest in cannabis and hemp reform, but these efforts remain tightly circumscribed by medical justifications and ongoing legal scrutiny

From the OG Lab newsroom perspective, this leadership change highlights the persistent ambiguity facing the cannabis industry as federal policy evolves. While the process to move marijuana to Schedule III appears intact, the underlying questions about who benefits—and under what terms—remain unresolved. Industry stakeholders should closely monitor further developments, as the interplay of politics, regulation, and litigation will shape the next chapter of U.S. cannabis reform